Abstract:LINC01126 is highly expressed in castration‐resistant prostate cancer and is correlated with poor prognosis. AR‐targeted therapies upregulate LINC01126 expression through relieving its transcriptional repression by AR. LINC01126 facilitates the activation of AR signalling independent of androgen. LINC01126 promotes the transition from O‐GlcNAcylation at threonine 80 to phosphorylation at S81 within the AR protein. AR‐targeted therapies inhibit synthesis of AR ligand or block binding of AR ligand to AR. Without AR ligand, AR protein is O‐GlcNAcylated at threonine 80 and degrades rapidly. LINC01126 is transcriptionally repressed by AR. AR‐targeted therapies thereby upregulate LINC01126 expression through relieving its transcriptional repression by AR. LINC01126 facilitates the interaction of AR with CDK9, resulting in AR S81 phosphorylation. Consequences of AR S81 phosphorylation are analogous to the effect of androgen on AR stability, nuclear translocation and transactivation. Therefore, LINC01126 facilitates the activation of AR signalling independent of androgen, contributing to progression of CRPC. LINC01126‐ASO that specifically interferes the binding of AR to CDK9 may have a possible therapeutic effect on CRPC. Background Prostate cancer (PCa) initially shows satisfactory response to therapies targeting the androgen receptor (AR). However, progression to a castration‐resistant stage indicates poor prognosis in PCa patients. AR signalling still plays a central role in most castration‐resistant prostate cancers (CRPC). Therefore, unveiling the mechanisms of AR reactivation under androgen‐deprived conditions is imperative to discover novel therapeutic targets for CRPC. Methods Using an integrative analysis of the transcriptomics of three independent PCa cohorts and a published landscape of AR‐regulated long non‐coding RNA (lncRNA), lncRNA LINC01126 was selected as a candidate gene that could drive CRPC progression for further study. Quantitative reverse transcription polymerase chain reaction, in situ hybridisation (ISH) and fluorescent ISH were performed to detect LINC01126 in PCa tissues and cells. The functional role and mechanism of LINC01126 were further investigated using in vitro and in vivo gain and loss of function assays. Results LINC01126, identified as an AR‐repressed lncRNA, was significantly upregulated after AR‐targeted therapies. In addition, we found that LINC01126 was upregulated in CRPC and was associated with poor prognosis. We also proved that LINC01126 stabilised AR protein and enhanced AR nuclear translocation and transactivation by promoting the transition from O‐GlcNAcylation at threonine 80 to phosphorylation at serine 81 (S81) within the AR protein. Mechanism analysis revealed that LINC01126 facilitates the interaction of CDK9 with AR and impedes the binding of O‐linked N‐acetylglucosamine (O‐GlcNAc) transferase to AR. Consequently, LINC01126 expression was sufficient to activate AR signalling without androgen. LINC01126 overexpression increased, whereas LINC01126 knockdown decreased castration resistance traits in PCa cells in vitro and in vivo. Furthermore, our data showed that LINC01126‐targeting antisense oligonucleotides (ASO) substantially inhibited CRPC cells in vitro. Conclusions Our research expands the functions of AR‐regulated lncRNA in sustaining androgen‐independent AR activity and promoting CRPC progression and reveals that LINC01126 may be a new therapeutic target for PCa.

Targeting the Lnc-OPHN1-5/Androgen Receptor/hnRNPA1 Complex Increases Enzalutamide Sensitivity to Better Suppress Prostate Cancer Progression

LINC00675 Activates Androgen Receptor Axis Signaling Pathway to Promote Castration-Resistant Prostate Cancer Progression

Olaparib and Enzalutamide Synergistically Suppress HCC Progression Via the AR-mediated Mir-146A-5p/brca1 Signaling.

The Androgen Receptor Variant ARv33 Increased Enzalutamide-Resistance in Prostate Cancer Via a Unique Trans-Splicing Mechanism

Orphan Nuclear Receptor TLX Contributes to Androgen Insensitivity in Castration-Resistant Prostate Cancer Via Its Repression of Androgen Receptor Transcription.

Abstract 2458: the Androgen Receptor-Regulated Lncrna Landscape Reveals a Role Forarlnc1in Prostate Cancer Progression

TP53 Inhibited AR Signaling Promote Enzalutamide Resistance in LNCaP cell

Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression

Expression of lncRNA PCGEM1 and AR co-localization in prostate cancer and tis signiifcance

PLXNA1 confers enzalutamide resistance in prostate cancer via AKT signaling pathway

LncRNA-p21 Alters the Antiandrogen Enzalutamide-Induced Prostate Cancer Neuroendocrine Differentiation Via Modulating the EZH2/STAT3 Signaling

Loss of Long Noncoding RNA NXTAR in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance

Lncrna-Dependent Mechanisms of Androgen-Receptor-regulated Gene Activation Programs

Understanding the development of enzalutamide resistance based on a functional single-cell approach

Long and noncoding RNAs (lnc-RNAs) determine androgen receptor dependent gene expression in prostate cancer growth in vivo.

Histone Acetyltransferase 1 Upregulates Androgen Receptor Expression to Modulate CRPC Cell Resistance to Enzalutamide.

Long and Noncoding RNAs (Lnc-Rnas) Determine Androgen Receptor Dependent Gene Expression in Prostate Cancer Growth in Vivo

Analysis of the Androgen Receptor-Regulated Lncrna Landscape Identifies a Role for ARLNC1 in Prostate Cancer Progression

Androgen‐repressed lncRNA LINC01126 drives castration‐resistant prostate cancer by regulating the switch between O‐GlcNAcylation and phosphorylation of androgen receptor

Targeting Androgen Receptor (AR) with Antiandrogen Enzalutamide Increases Prostate Cancer Cell Invasion Yet Decreases Bladder Cancer Cell Invasion Via Differentially Altering the AR/circRNA-ARC1/miR-125b-2-3p or Mir-4736/Pparγ/mmp-9 Signals

Increased Prlz-Mediated Androgen Receptor Transactivation Promotes Prostate Cancer Growth At Castration-Resistant Stage